Literature DB >> 3390998

Disposition and irreversible plasma protein binding of tolmetin in humans.

M L Hyneck1, P C Smith, A Munafo, A F McDonagh, L Z Benet.   

Abstract

The pharmacokinetics and irreversible plasma protein binding of tolmetin were studied in six healthy subjects after the administration of a single, 400 mg dose of tolmetin. With HPLC analysis, tolmetin, tolmetin glucuronide, and the isomers of tolmetin glucuronide, which result from intramolecular acyl migration in vivo, were detected in the plasma up to 4 hours after administration, whereas these conjugates were present in the urine up to 24 hours. Irreversible binding of tolmetin to plasma proteins occurred in all subjects. Irreversible binding exhibited a better correlation with exposure to tolmetin glucuronide (r = 0.5618) and the isomers of tolmetin glucuronide (r = 0.8200) than with exposure to tolmetin (-0.3635). This is consistent with the hypothesis that covalent binding occurs via the acyl glucuronide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390998     DOI: 10.1038/clpt.1988.120

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.

Authors:  R K Verbeeck; G R Loewen; J I MacDonald; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

3.  A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Authors:  Daniel Moj; Hugo Maas; André Schaeftlein; Nina Hanke; José David Gómez-Mantilla; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

4.  Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients.

Authors:  Thomas G Hammond; Xiaoli Meng; Rosalind E Jenkins; James L Maggs; Anahi Santoyo Castelazo; Sophie L Regan; Stuart N L Bennett; Caroline J Earnshaw; Guruprasad P Aithal; Ira Pande; J Gerry Kenna; Andrew V Stachulski; B Kevin Park; Dominic P Williams
Journal:  J Pharmacol Exp Ther       Date:  2014-06-05       Impact factor: 4.030

5.  Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Authors:  Nagsen Gautam; Rhishikesh Thakare; Sandeep Rana; Amarnath Natarajan; Yazen Alnouti
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

6.  Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry.

Authors:  A Ding; J C Ojingwa; A F McDonagh; A L Burlingame; L Z Benet
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

7.  Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisal.

Authors:  R G Dickinson; A R King; G E McKinnon; W D Hooper; M J Eadie; G K Herkes
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

8.  Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma.

Authors:  J C Ojingwa; H Spahn-Langguth; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

9.  Irreversible binding of tolmetin glucuronic acid esters to albumin in vitro.

Authors:  A Munafo; A F McDonagh; P C Smith; L Z Benet
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

10.  Synthesis and mass-spectrometric characterization of human serum albumins modified by covalent binding of two non-steroidal anti-inflammatory drugs: tolmetin and zomepirac.

Authors:  P Zia-Amirhosseini; A Ding; A L Burlingame; A F McDonagh; L Z Benet
Journal:  Biochem J       Date:  1995-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.